allergx
AllergX is an RNA-based therapeutic framework that targets the root cause of allergic responses through programmable aptaswitches. rather than suppressing symptoms with antihistamines or relying on long-term immunotherapy, it directly regulates Immunoglobulin E (IgE) via precision molecular logic — treating the mechanism, not the outcome.
the mechanism
allergic responses are driven by IgE antibodies binding to allergens and triggering mast cell degranulation — releasing histamines and other inflammatory mediators. existing treatments either block the downstream effects (antihistamines) or attempt to retrain the immune system over years (immunotherapy). AllergX intervenes upstream: programmable RNA aptamers designed to bind allergen-specific IgE and block the signaling cascade before it escalates.
aptaswitch design
aptaswitches are RNA molecules engineered with conditional logic — they activate only when specific molecular conditions are met. AllergX uses SELEX (systematic evolution of ligands by exponential enrichment) to discover aptamers targeting IgE and key Th2 cytokines. the system is modular and logic-gated: it can be tuned to specific allergen profiles and turned on or off based on IgE concentration, enabling on-demand immune regulation.
delivery and personalization
the therapeutic framework is designed to accommodate multiple delivery strategies — oral, subcutaneous, or microencapsulated depending on the allergen and patient profile. because the aptaswitch is programmed for specific IgE variants, the treatment is inherently personalizable. two patients with peanut allergies may trigger different IgE populations; AllergX can target both.
broader vision
the long-term aim extends this platform to related conditions — asthma, atopic dermatitis, and food allergies — where dysregulated Th2 activity is the common denominator. AllergX represents a shift from reactive symptom management to proactive immune system reprogramming.